Armstrong AJ, Halabi S, Luo J, et al. The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). J Clin Oncol 36, 2018 (suppl; abstr 5004).
Zorginstituut adviseert over toelating pembrolizumab (Keytruda) bij TNBC
mei 2024 | Borstkanker